C. Y. Cheah, J. F. Seymour, and M. L. Wang, Mantle cell lymphoma, J Clin Oncol, vol.34, pp.1256-69, 2016.

M. Dreyling and S. Ferrero, The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?, Haematologica, vol.101, pp.104-118, 2016.

J. B. Cohen, J. M. Zain, and B. S. Kahl, Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies, Am Soc Clin Oncol Educ Book, vol.37, pp.512-537, 2017.

M. L. Wang, S. Rule, and P. Martin, Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, pp.507-523, 2013.

J. J. Buggy and L. Elias, Bruton tyrosine kinase (BTK) and its role in B-cell malignancy, Int Rev Immunol, vol.31, pp.119-151, 2012.

. Pharmacyclics, Imbruvica package insert, 2017.

D. C. Saffran, O. Parolini, and M. E. Fitch-hilgenberg, Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia, N Engl J Med, vol.330, pp.1488-91, 1994.

Q. Zhu, M. Zhang, J. Winkelstein, S. H. Chen, and H. D. Ochs, Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families, Hum Mol Genet, vol.3, pp.1899-900, 1994.

D. M. Stephens and S. E. Spurgeon, Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion, Ther Adv Hematol, vol.6, pp.242-52, 2015.

J. C. Byrd, B. Harrington, and S. O'brien, ACP-196) in relapsed chronic lymphocytic leukemia, N Engl J Med, vol.374, pp.323-355, 2016.

S. Kamel, L. Horton, and L. Ysebaert, Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation, Leukemia, vol.29, pp.783-87, 2015.

T. Covey, M. Gulrajan, and F. Krantz, ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients, Cancer Res, vol.75, p.2596, 2015.

T. Barf, T. Covey, and R. Izumi, ACP-196): a covalent Bruton tyrosine kinase (BTK) inhibitor with a differentiated selectivity and in vivo potency profile, J Pharmacol Exp Ther, vol.363, pp.240-52, 2017.

B. D. Cheson, R. I. Fisher, and S. F. Barrington, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, vol.32, pp.3059-68, 2014.

B. D. Cheson, B. Pfistner, and M. E. Juweid, Revised response criteria for malignant lymphoma, J Clin Oncol, vol.25, pp.579-86, 2007.

R. Simon, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, vol.10, pp.1-10, 1989.
DOI : 10.1016/0197-2456(89)90015-9

URL : http://linus.nci.nih.gov/techreport/Optimal2-StageDesigns.pdf

D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, vol.16, pp.139-183, 1998.

B. Y. Chang, M. Francesco, D. Rooij, and M. F. , Egress of CD19(+) CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, pp.2412-2436, 2013.

M. S. Davids and J. A. Burger, Cell trafficking in chronic lymphocytic leukemia, Open J Hematol, vol.3, issue.1, p.3, 2012.

A. Wiestner, The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia, Haematologica, vol.100, pp.1495-507, 2015.

A. Burkle, M. Niedermeier, A. Schmitt-graff, W. G. Wierda, M. J. Keating et al., Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia, Blood, vol.110, pp.3316-3341, 2007.

K. D. Jayappa, C. A. Portell, and V. L. Gordon, Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL, Blood Adv, vol.1, pp.933-979, 2017.

S. Ponader, S. S. Chen, and J. J. Buggy, The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo, Blood, vol.119, pp.1182-89, 2012.

M. F. De-rooij, A. Kuil, and C. R. Geest, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia, Blood, vol.119, pp.2590-94, 2012.